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Oral multiparticulate systems show several advantages in comparison with single
unit dosage forms, such as more predictable gastric emptying, gastric emptying less de-
pendent on the state of nutrition, high degree of dispersion in the digestive tract, lesser
risk of dose dumping and reduced local irritation (1).
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A 32 factorial design was employed to produce glipizide
lipospheres by the emulsification phase separation tech-
nique using paraffin wax and stearic acid as retardants.
The effect of critical formulation variables, namely levels
of paraffin wax (X1) and proportion of stearic acid in the
wax (X2) on geometric mean diameter (dg), percent encap-
sulation efficiency (% EE), release at the end of 12 h (rel12)
and time taken for 50% of drug release (t50), were evaluated
using the F-test. Mathematical models containing only the
significant terms were generated for each response para-
meter using the multiple linear regression analysis (MLRA)
and analysis of variance (ANOVA). Both formulation vari-
ables studied exerted a significant influence (p < 0.05) on
the response parameters. Numerical optimization using
the desirability approach was employed to develop an op-
timized formulation by setting constraints on the depend-
ent and independent variables. The experimental values
of dg, % EE, rel12 and t50 values for the optimized formu-
lation were found to be 57.54 ± 1.38 mm, 86.28 ± 1.32%,
77.23 ± 2.78% and 5.60 ± 0.32 h, respectively, which were
in close agreement with those predicted by the mathema-
tical models. The drug release from lipospheres followed
first-order kinetics and was characterized by the Higuchi
diffusion model. The optimized liposphere formulation
developed was found to produce sustained anti-diabetic
activity following oral administration in rats.
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Though a number of microencapsulation techniques have been employed to pro-
duce peroral polymeric multiparticulate systems (2), the toxicity of the residual organic
solvent in the final product and the use of potentially toxic monomers are the major con-
cerns with these conventional microencapsulation techniques (3). In order to overcome
these problems, the melt dispersion method has been proposed as a simple and useful
technique to produce lipospheres without using any harmful organic solvents (4).
Glipizide is an oral hypoglycemic agent, which is a commonly prescribed drug for
the treatment of patients with type II diabetes mellitus (5). It is a weak acid (pKa = 5.9)
practically insoluble in water and acidic environment but highly permeable (class 2) ac-
cording to the Biopharmaceutical Classification System (BCS) (6). The oral absorption is
uniform, rapid and complete with a bioavailability of nearly 100% and an elimination
half-life of 2–4 h (6). Glipizide is reported to have a short biological half-life (3.4 ± 0.7 h)
requiring it to be administered in 2 to 3 doses of 2.5 to 10 mg per day (7). Though a num-
ber of multiparticulate systems have been proposed for peroral controlled delivery of
glipizide, most of them were polymeric drug delivery systems produced by conventio-
nal microencapsulation techniques (8, 9).
Use of the response surface methodology has been proved to be a useful tool in the
development and optimization of controlled release microspheres (8). Different steps in-
volved in response surface methodology include experimental design, regression analy-
sis, constraint optimization and validation.
The current research was aimed at developing controlled release glipizide lipospheres
employing the melt dispersion method since no such methods to produce glipizide lipo-
spheres have been reported earlier.
EXPERIMENTAL
Materials
Glipizide was a generous gift sample from M/s Micro Labs (India). Paraffin wax
was procured from Glaxo Laboratories Ltd. (India). Stearic acid, Tween 80, potassium
dihydrogen orthophosphate, disodium hydrogen orthophosphate and sodium hydrox-
ide were purchased from S.D. Fine Chemicals Ltd. (India). All the other regents and che-
micals used were of analytical grade.
Experimental design
A 2 factor 3 levels full factorial design was employed to design controlled release
lipospheres of glipizide (10). This design was suitable for exploring quadratic response
surfaces and constructing second-order polynomial models. The two independent for-
mulation variables analyzed during the study were the percentage wax loads in the lipo-
sphere formulation (X1) and the proportion of stearic acid in the wax (X2). The dependent
variables investigated were the geometric mean diameter (Y1), encapsulation efficiency
(Y2), drug release at the end of 12 hours (Y3) and the time taken for 50% of the drug to be
released (Y4).
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Preparation of drug loaded lipospheres
Glipizide lipospheres were prepared employing a modified hydrophobic congeal-
able dispersed phase encapsulation procedure (4). The mixture of paraffin wax and stearic
acid was melted to obtain a one-phase melt on a thermostated hot plate (2 MLH, Remi
Equipments Ltd., India). Glipizide was dispersed in the molten wax and the tempera-
ture of the resulting oily phase was maintained at 70 °C. The surfactant solution com-
prising 1% (V/V) of Tween 80 in water was maintained at a temperature of 80 °C under
continuous stirring using a propeller stirrer (RQ 121 D, Remi Equipments Ltd.). The
molten oily phase was emulsified in the aqueous surfactant solution maintained at 900
rpm. Hardening of the oily internal phase resulting in encapsulation of the drug was ac-
complished by pouring twice the emulsion volume of ice cold water maintained at 4 °C.
The resulting lipospheres were separated by filtration, washed with ice cold water and
dried at room temperature (25 °C) for 24 hours. A total of 9 batches (F1 to F9) of gli-
pizide lipospheres were produced as per 32 full factorial design by varying the drug to
wax ratio and levels of stearic acid (Table I). The other formulation and processing vari-
ables were maintained constant during the process.
Characterization of lipospheres
Particle size distribution. – The number distribution of different batches of lipospheres
was determined by optical microscopy (4). The projected diameter of a total of 200 lipo-
spheres from each batch was determined using an image analyzer (Labomed, India) that
consisted of a optical microscope linked to a computer and a digital camera. The digita-
lized images captured were analyzed by image analyzing software (Digipro version 2,
Labomed). The geometric mean diameter (dg) and standard deviation (sg) were com-
puted by fitting the number distribution data into log normal plots (11).
Encapsulation efficiency. – An accurately weighed quantity of drug loaded lipospheres
was pulverized and digested in sodium hydroxide (0.1 mol L–1). The drug was extracted
with the solvent overnight, filtered and the amount of glipizide in the filtrate was as-
sayed after appropriate dilution by measuring the absorbance at 223 nm in a UV-visible
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spectrophotometer (Shimadzu UV 1700 PC, Shimadzu, Japan). The drug content was es-
timated in triplicate using a calibration curve constructed in the same solvent (9). The
percentage encapsulation efficiency of different batches of lipospheres was calculated from
the percentage drug content values.
In vitro drug release studies. – Dissolution studies were performed over a period of 12
hours in a USP XXIV (12) basket dissolution apparatus [TDL-08 L, Electrolab (I) Ltd., In-
dia] at a stirring speed of 100 rpm. Release studies of the glipizide and drug loaded lipo-
spheres were carried out using phosphate buffer of pH 7.4 (900 mL), maintained at 37 ±
0.5 °C, as a dissolution medium (9). Aliquots of samples withdrawn every hour were fil-
tered though 0.45-mm filter, appropriately diluted, and assayed spectrophotometrically
at 223 nm. The raw dissolution data recorded in triplicate was analyzed to calculate the
percentage of cumulative drug released at different time intervals.
Data fitting. – An attempt was made to fit the dissolution data into the Higuchi dif-
fusion model (13) represented:
(1)
Mt stands for the amount of drug released at t and KH is the Higuchi rate constant.
The data was also treated with the Korsmeyer-Peppas model (14) to characterize the me-
chanism of drug release:
(2)
Mt/M¥ represents the fraction of drug released at time t and Kp is the kinetic con-
stant characterizing the polymeric system and n stands for the diffusion exponent.
The dissolution data was also analyzed using the first-order equation (15) to deter-
mine the kinetics of drug release from different batches of lipospheres:
(3)
The curve fitting, simulation and plotting was performed in Excel (Microsoft Soft-
ware Inc., USA) and Graph Pad Prism® version 3.02 (Graph Pad Software Inc., USA).
Regression analysis. – The targeted response parameters were statistically analyzed
by applying one-way ANOVA at 0.05 level in the Design-Expert® 6.0.5 demo version
soft ware (Stat-Ease Inc., USA). Individual response parameters were evaluated using
the F-test and quadratic models of the form given below were generated for each re-
sponse parameter using the multiple linear regression analysis (16):
(4)
where Y is the level of the measured response, b0 is the intercept, b1 to b5 are the regres-
sion coefficients, X1 and X2 stand for the main effects, X1X2 is the interaction between the
main effects, X1
2 and X2
2 are the quadratic terms of the independent variables that were
used to simulate the curvature of the designed sample space. A backward elimination
procedure was adopted to fit the data to the quadratic model. The quadratic models ge-
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nerated from the regression analysis were used to construct the 3-dimensional graphs, in
which the response parameter Y was represented by a curvature surface as a function of
X. The effects of independent variables on the response parameters were visualized from
the contour plots.
Numerical optimization using the desirability approach was employed to locate the
optimal settings of the formulation variables to obtain the desired response (16). An op-
timized formulation was developed by setting constraints on the dependent and inde-
pendent variables. The formulation developed was evaluated for the responses and the
experimental values obtained were compared with those predicted by the mathematical
models generated.
Scanning electron microscopy. –Morphology and surface topography of the lipospheres
were examined by scanning electron microscopy (3). The lipospheres from the optimized
batch (F10) were mounted on the SEM sample stab using a double-sided sticking tape
and coated with gold (~200 nm) under reduced pressure (0.133 Pa) for 5 min using an
Ion sputtering device (JFC-1100 E, JEOL, Japan). The gold coated lipospheres were ob-
served under the scanning electron microscope (JSM-840 A, JEOL) and photomicrographs
of suitable magnifications was obtained.
Differential scanning calorimetry. – Thermograms of glipizide, placebo lipospheres and
optimized liposphere formulation (F10) were recorded in a differential scanning calori-
meter (Pyris-1, Perkin Elmer, USA) to characterize the solid state of the drug in the wax
matrix. The samples were placed in flat bottomed aluminum pans and heated over a
temperature range of 40–180 °C at a constant rate of 5 °C min–¹ with purging of nitrogen
(50 mL min–1), using alumina as a reference standard.
In vivo study. – In vivo evaluation of glipizide lipospheres was performed on healthy
albino Wistar rats weighing between 250 and 300 g (8). Approval of the Institutional Animal
Ethics Committee was obtained before the study. Two groups of rats (4 in each group)
fasted for 12 hours with free access to water were used for the study. Stock suspensions
of either the drug or the drug loaded lipospheres containing glipizide at a concentration
of 200 mg mL–1 were used for oral administration. The suspensions were administered
orally at a dose equivalent to 800 mg kg–1 of glipizide to respective groups using stomach
intubation. Blood samples were withdrawn at predetermined time intervals of 0, 1, 2, 4,
6, 8, 10, 12 and 24 hours by retroorbital puncture. The blood sample withdrawn at time 0
was considered as control. The blood glucose level of the control and test samples were
determined using the glucose-measuring instrument Accu-check active (Roche Diagnos-
tics, USA). The percentage reduction in blood glucose levels was computed and plotted
against time.
RESULTS AND DISCUSSION
The melt dispersion technique employed to produce drug loaded lipospheres is ideal
for encapsulation of water insoluble drugs (4). Due to its poor aqueous solubility (6),
glipizide was selected as drug candidate to prepare lipospheres employing the melt dis-
persion technique. Since lipospheres produced with paraffin wax alone resulted in poor
drug release, efforts were made to enhance drug release from the lipospheres by incor-
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porating a wax modifier like stearic acid. Literature citations reveal that stearic acid has
been successfully employed as a wax modifier to modulate drug release from wax mi-
crospheres (3). Tween 80 was used to stabilize the oil in water emulsion by reducing the
interfacial tension between the hydrophobic wax dispersion and the external aqueous
phase, producing an emulsified oily dispersion, which resulted in drug loaded lipospheres
on cooling.
The independent variables and their levels were selected based on the preliminary
trials undertaken. The trials revealed that low wax payloads (< 20%) failed to produce
lipospheres with acceptable physical characteristics whereas high wax loads (> 80%) re-
sulted in lipospheres that exhibited poor drug release (< 40% at the end of 12 h). Based
on these observations, the lower and higher levels of percentage drug loading were re-
tained at 25% and 75%, respectively, during the run.
As drug release from the lipospheres with paraffin wax alone was inherently sus-
tained, stearic acid was used as a wax modifier. Since stearic acid at concentrations ex-
ceeding 50% of wax load resulted in poor encapsulation efficiencies (< 80%), the lower
and higher levels of the wax modifier were maintained at 0 and 40% of the total wax
loads, respectively, during the run.
The other formulation variables, such as the amount of emulsifier, volume of the ex-
ternal aqueous phase and the processing variables like stirring speed, stirring time and
the temperature of emulsification, were maintained constant during the study.
SEM photomicrographs (Fig. 1a) revealed that the optimized liposphere formulations
(F10) were more or less spherical with a rough surface. Numerous drug crystals were
clearly evident under high magnification (Fig. 1b) which can be attributed to the high
drug loads in the lipospheres. The drug crystallized on the surface of the lipospheres
once the drug concentration in the lipospheres exceeded its solubility in the wax matrix.
Optical microscopic image analysis revealed that the lipospheres of different batches
exhibited a narrow size distribution, with particles ranging in size between 20 to 150 mm.
The number distribution data obtained when represented as log-probability plots gave
straight lines, indicating a log-normal distribution for all batches of the lipospheres pro-
duced. The geometric mean diameters for different batches of lipospheres were found to
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Fig. 1. Scanning photomicrographs of glipizide lipospheres: a) under low magnification,
b) under high magnification.
range from 47.86 to 69.18 mm. The corresponding standard deviation values ranged be-
tween 1.32 and 1.44 (Table II).
High encapsulation efficiencies ranging from 82.76 ± 1.11% to 95.66 ± 0.99% (Table
II) were recorded for different batches of lipospheres produced. The values indicated
that the drug encapsulation depended on the levels of wax as well as on wax composi-
tion, which influenced the drug wax compatibility. The high values of encapsulation ef-
ficiency can also be ascribed to the lipophilic nature of the drug, which got easily wetted
and finely dispersed in the molten wax phase prior to emulsification.
The amount of drug released from the lipospheres at the end of 12 h of dissolution
are shown in Table II along with the t50 values. As mentioned earlier, the pKa of glipizide
is reported to be 5.9. The solubility is found to increase significantly above the pKa value
of the drug. Considering this, the USP recommends to study the dissolution at pH 6.8
buffer (12). Since under these pH conditions the sink conditions are not fully met (18),
the dissolution studies were performed at pH 7.4 so as to ensure that the sink conditions
are met. The drug release profiles of glipizide and drug loaded lipospheres are shown in
Fig. 2. Drug release from the lipospheres depended on the wax payloads and the stearic
acid levels. Lipospheres produced with paraffin wax alone showed slow drug release,
ranging from 50.18 ± 2.35% to 63.89 ± 2.19%, by the end of 12 h of dissolution. The slow
release indicated efficient encapsulation of the lipophilic drug in the wax, resulting in a
compact dense wax matrix that posed a significant hindrance to fluid penetration and
passive drug diffusion.
Even though diffusional systems are supposed to be a poor choice for slightly solu-
ble drugs (18), a microporous matrix system in the form of wax microspheres is reported
to be an ideal choice for poorly water-soluble drugs (15). Incorporation of stearic acid is
reported to render the liposphere microporous and enhance the release of the poorly solu-
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Table II. Factor combinations and response parameters of glipizide lipospheres













F1 –1 (25) –1 (0) 52.48 ± 1.38 87.12 ± 1.44 63.89 ± 2.32 8.57 ± 0.55
F2 0 (50) –1 (0) 63.10 ± 1.38 92.23 ± 0.82 55.09 ± 2.34 10.80 ± 0.60
F3 +1 (75) –1 (0) 69.18 ± 1.45 95.66 ± 0.99 51.18 ± 1.14 11.60 ± 0.40
F4 –1 (25) 0 (20) 50.12 ± 1.32 88.46 ± 1.47 87.89 ± 2.26 4.33 ± 0.25
F5 0 (50) 0 (20) 57.54 ± 1.44 89.12 ± 0.98 76.47 ± 2.32 7.63 ± 0.45
F6 +1 (75) 0 (20) 66.07 ± 1.38 92.45 ± 1.62 66.12 ± 2.48 8.33 ± 0.45
F7 –1 (25) +1 (40) 47.86 ± 1.32 82.76 ± 1.11 91.26 ± 4.77 4.37 ± 0.31
F8 0 (50) +1 (40) 54.95 ± 1.38 86.24 ± 1.55 83.21 ± 2.58 4.60 ± 0.30
F9 +1 (75) +1 (40) 60.26 ± 1.44 90.66 ± 1.73 76.52 ± 3.14 6.07 ± 0.60
X1 – percent wax load, X2 – percent of stearic acid in the wax, dg – geometric mean diameter, EE – encapsula-
tion efficiency, rel12 – release at the end of 12 h, t50 – time taken for 50% of the drug release.
a The parentheses in the data represent the decoded factor levels.
b Mean ± SD, n = 3.
ble drug (3). The drug release from lipospheres in which 20% of the wax is replaced with
stearic acid was found to range from 66.12 ± 3.25% to 87.89 ± 0.73% after 12 hours of dis-
solution, indicating enhancement of drug release in the presence of the modifier.
Lipospheres in which 40% of the wax was substituted with stearic acid further enhanced
the drug release since 76.52 ± 3.54% to 91.26 ± 1.89% of the drug was released at the end
of the dissolution period.
The predictor equation generated for the geometric mean diameter (dg) was found
to be significant with an F-value of 132.24 (p < 0.0001) and R2 value of 0.9778:
(5)
The equation generated revealed that both main factors independently exerted a
significant influence on the mean diameter. The influence of the main effects on the par-
ticle size of the lipospheres was further elucidated using the response surface plot (Fig.
3a). The mean diameter increased from 52.48 ± 1.38 mm to 69.18 ±1.45 mm and from 47.86
± 1.32 mm to 60.26 ± 1.44 mm at lower and higher levels of stearic acid, respectively, as
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Fig. 2. In vitro drug release
from glipizide and drug load-
ed lipospheres prepared as
per 32 factorial design (mean
± SD, n = 3).
1 1 2Y 57.95 7.51X 3.62 X–= +
the wax loads increased. This was probably due to the inherent tackiness of the wax,
leading to larger particles as the wax loads increased. An increase in the particle size of
wax microspheres at higher wax loads was reported earlier (19).
The liposphere size reduced from 69.18 ± 1.45 mm to 60.26 ± 1.44 mm and from 52.48
± 1.38 mm to 47.86 ± 1.32 mm at high and low wax loads, respectively, as the stearic acid
levels increased. This could be attributed to the drop in viscosity of the dispersed wax
phase on incorporation of the low viscosity melt, which resulted in formation of smaller
droplets of the drug wax suspension during emulsification (3). The corresponding con-
tour plots were linear and indicated that the number of fins can be minimized using higher
wax loads coupled with lower stearic acid levels.
The linear model generated for encapsulation efficiency was found to be significant
with an F-value of 34.42 (p < 0.0005) and R2 value of 0.9198:
(6)
The model indicated that both the factors studied exerted independently a signifi-
cant influence on the encapsulation efficiency. The 3-D plot (Fig. 3b) shows that the en-
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Fig. 3. Response surface plot showing the effect of wax loads (X1) and stearic acid levels (X2) on: a)
mean diameter (Y1), b) encapsulation efficiency (Y2), c) release at the end of 12 hours (Y3), and d)
time taken for 50% drug release (Y4).
–1 22
Y = 89.41 + 3.40 X 2.56 X
capsulation efficiency increased from 87.12 ± 1.44% to 95.66 ± 0.99% and from 82.76 ±
1.11% to 90.66 ± 1.73% at lower and higher levels of stearic acid, respectively, as the wax
levels increased. This improvement in encapsulation efficiency with an increase in wax
levels was due to efficient wetting and dispersion of the drug in the molten wax at high-
er wax loads. In contrast, encapsulation efficiency declined from 87.12 ± 1.44% to 82.76 ±
1.11% and from 95.66 ± 0.99% to 90.66 ± 1.73% at high and low wax loads, respectively,
as stearic acid levels increased, which could be due to the presence of the carboxylic group
in stearic acid, which resulted in poor wetting of the hydrophobic drug in the molten
wax (3). This caused inadequate dispersion of the drug in the molten wax, resulting in
lower drug encapsulation at higher stearic acid levels. As a consequence, drug crystals
were visible on the outer surface of the lipospheres at higher stearic acid levels. A linear
relationship between the two variables of encapsulation efficiency was clearly visible from
the corresponding contour plots, which suggested that encapsulation efficiency can be
enhanced using low stearic acid levels at high wax loads.
The second order polynomial model generated for release at the end of 12 h was
significant with F-value of 121.95 (p < 0.0001) and R2 value of 0.9865:
(7)
The quadratic model generated revealed that the levels of wax and stearic acid had
a significant antagonistic influence on the drug release, without producing any interac-
tion. The wax loads were found to have a negative influence on the drug release since
glipizide release at the end of 12 hours of dissolution showed a decline with an increase
in the levels of wax. The response surface plots (Fig. 3c) illustrate that the drug release at
the end of 12 hours decreased from 63.89 ± 2.19% to 50.18 ± 2.35% and from 91.26 ±
1.89% to 76.52 ± 3.54% at low and high levels of stearic acid, respectively, as the wax
loads increased. The quicker drug release at low wax loads can be due to increased drug
crystals positioned on the liposphere surface that remained exposed to the dissolution
fluid (3). At higher drug loads, drug dissolution resulted in a subsequent increase in the
number of channels and pores within the wax matrix, which decreased the diffusional
path length through the drug depleted zone and enhanced drug release (20).
Stearic acid levels were found to have a positive influence on drug release since the
drug release improved on incorporation of stearic acid. It was evident from the 3-D plots
that the drug release at the end of 12 hours enhanced from 63.89 ± 2.19% to 91.26 ± 1.89%
and from 50.18 ± 2.35% to 76.52 ± 3.54% at low and high wax levels, respectively, as the
stearic acid levels increased. This enhancement in drug release can be ascribed to the po-
lar carboxylic acid groups in stearic acid, which made the matrix more susceptible to
hydration and thereby created a hydrophilic pathway for water molecules to access the
drug (20). This decreased the resistance to diffusion of the dissolution fluid through the
wax matrix and increased the drug dissolution. The lower melting point and density of
stearic acid also reported to be contributing factors to enhancing the drug release from
the heterogeneous wax matrix systems (21). The corresponding contour plots illustrate
that the drug release at the end of 12 hours can be maximized by using low wax loads
coupled with high stearic acid levels.
The mathematical model generated for time taken for 50% drug release was found
to be significant with F-value of 35.14 (p < 0.0005) and R2 value of 0.9213:
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2
3 1 2 2Y = 76.83 – 8.37 X + 13.64 X – 6.80 X
(8)
The mathematical model generated indicated that both the wax loads and stearic
acid levels were found to exert independently a significant influence on t50. The positive
influence of wax levels on t50 is clearly demonstrated by the response surface plots (Fig.
3d), which indicate that the t50 increased from 8.57 ± 0.55 hours to 11.60 ± 0.40 hours and
from 4.33 ± 0.25 hours to 6.07 ± 0.60 hours at low and high stearic acid levels, respec-
tively, as the wax loads increased. The slower drug release with increased wax loads was
due to better encapsulation of the lipophilic drug in the wax matrix, which resulted in
high t50 values. The 3-D plots also show that the t50 reduced 8.57 ± 0.55 hours to 4.33 ±
0.25 hours and from 11.60 ± 0.40 hours and 6.07 ± 0.60 hours at lower and higher wax
loads as the stearic acid content increased, namely from 8.57 ± 0.55 hours to 4.33 ± 0.25
hours and from 11.60 ± 0.40 hours to 6.07 ± 0.60 hours at lower and higher wax loads, re-
spectively. This can be attributed to the hydrophilic and leaching property of stearic acid,
which increased the magnitude of the voids and consequently the channels from the li-
posphere surface, resulting in the formation of a heavily structured, and microporous
matrix (3). The corresponding contour plots indicated a linear relationship between the
two variables investigated and t50. It was evident from the contour plots that t50 can be
minimized using low wax loads with high levels of stearic acid.
The results of curve fitting into different mathematical models are given in Table III.
The mechanism of drug release from the lipospheres was found to be diffusion control-
led because plots of percent cumulative drug release vs. square root of time were found to
be linear with the regression coefficient (R2) values ranging from 0.950 to 0.990 for the
nine formulations. The value of the Higuchi rate constant (13) was found to vary be-
tween 13.37 ± 0.31 to 25.47 ± 0.95 h–1/2, showing an increasing trend as the wax level de-
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4 1 2Y = 7.47 + 1.46 X – 2.66X
Table III. Results of curve fitting of the dissolution data for the lipospheres
prepared as per 32 factorial design
Batch code
Korsmeyer Peppas Higuchi First-order
na KP (h–n)a KH (% h–1/2)a K1a (h–1)
F1 0.34 ± 0.02 0.528 ± 0.006 15.64 ± 1.30 0.066 ± 0.001
F2 0.41 ± 0.01 0.467 ± 0.005 14.19 ± 0.60 0.055 ± 0.001
F3 0.42 ± 0.01 0.446 ± 0.006 13.37 ± 0.31 0.051 ± 0.001
F4 0.38 ± 0.02 0.572 ± 0.007 24.22 ± 0.49 0.140 ± 0.001
F5 0.37 ± 0.04 0.514 ± 0.011 20.67 ± 0.45 0.092 ± 0.001
F6 0.41 ± 0.03 0.481 ± 0.009 17.97 ± 0.54 0.071 ± 0.001
F7 0.28 ± 0.04 0.599 ± 0.010 25.47 ± 0.94 0.155 ± 0.002
F8 0.36 ± 0.03 0.568 ± 0.008 22.36 ± 0.63 0.119 ± 0.002
F9 0.39 ± 0.03 0.529 ± 0.008 21.62 ± 1.01 0.097 ± 0.001
n – diffusion exponent, KP – kinetic constant, KH – Higuchi rate constant, K1 – first-order rate constant.
a Mean ± SD, n = 3.
creased and stearic acid level increased. Since the liposphere size did not change after
complete exhaustion of the drug during dissolution, the release data representing the
first 60% of the drug release was further analyzed using the Korsmeyer-Peppas equation
(14) to further characterize the diffusional release. The Korsmeyer-Peppas model has been
employed to distinguish between the two competing release mechanisms, a Fickian (non-
-steady) diffusional release when n £ 0.43 and a case-II transport (zero-order kinetics)
when n ³ 0.85 (14). The low values of the diffusion exponent (0.28 ± 0.04 to 0.42 ± 0.01)
indicated the Fickian diffusional release and at the same time ruled out the possibilities
of erosion or solubilization of the wax matrix.
The kinetics of drug release from the liposphere was found to follow first-order ki-
netics (15) as the plots of log concentration of drug retained vs. time were linear (R2 value
ranged from 0.941 to 0.982) with the values of the first-order rate constant ranging from
0.055 ± 0.001 to 0.155 ± 0.002 h–1.
The results of ANOVA, as shown in Table IV, indicated that the model was signifi-
cant for all response parameters investigated. The multiple linear regression analysis
performed revealed that both the formulation variables analyzed had a significant influ-
ence on all response parameters. The results obtained collectively indicate that optimum
amounts of wax and wax modifier are essential to produce lipospheres with desirable
encapsulation and release characteristics.
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Table IV. Summary of ANOVA for the response parameters of lipospheres
prepared as per 32 factorial design
Source d.f. Sum square Mean square F-value Probability > F
dg (mm) R
2 = 0.9778
Model 2 416.66 208.33 132.24 < 0.0001
X1 1 338.25 338.25 214.71 < 0.0001
X2 1 78.41 78.41 49.77 0.0004
EE (%) R2 = 0.9198
Model 2 108.83 54.42 34.42 0.0005
X1 1 69.56 69.56 44.00 0.0006
X2 1 39.27 39.27 24.84 0.0025
Rel12 (%) R
2 = 0.9865
Model 3 1628.89 542.96 121.95 < 0.0001
X1 1 420.34 420.34 94.41 0.0002
X2 1 1116.02 1116.04 250.66 < 0.0001
X2 1 92.53 92.53 20.78 0.0061
t50 (h) R
2 = 0.9317
Model 2 59.55 29.78 40.91 0.0003
X1 1 14.73 14.73 20.24 0.0041
X2 1 44.83 44.83 61.59 0.0002
X1 – percent wax loads, X2 – percent of stearic acid in the wax, X22 – quadratic term of X2.
A numerical optimization technique using the desirability approach was employed
to develop a new formulation with the desired responses. Constraints like maximizing
the encapsulation efficiency and release at the end of 12 hours in addition to minimizing
the t50 were set as goals to locate the optimum settings of independent variables in the
new formulation.
The optimized liposphere formulation (F10) was developed using 34.3% of glipizi-
de, 39.4% of paraffin wax and 26.3% of stearic acid. The optimized formulation was eva-
luated for particle size, encapsulation efficiency and drug release. Table V lists the val-
ues of the observed responses and those predicted by mathematical models along with
the percentage prediction errors. The prediction error for the response parameters rang-
ed between 1.50 and 3.15% with the value of absolute error of 2.36 ± 0.70%. The low val-
ues of error indicate the high prognostic ability of response surface methodology. Model
reduction using MLRA by eliminating insignificant terms has already been reported to
result in better prognosis of the performance of the optimized formulation (16). The drug
release from the optimized formulation was found to follow first-order kinetics and was
characterized by the Fickian diffusion model.
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Table V. Comparison of experimentally observed responses of the optimized liposphere
formulation with that of predicted responses
Response parameters Constraints set Observed valuesa Predicted values Error (%)
dg (mm) in the range 57.54 ± 1.38 59.06 2.6
EE (%, m/m) maximize 86.28 ± 1.32 89.00 3.2
rel12 (%) maximize 77.23 ± 2.78 78.39 1.5
t50 (h) minimize 5.60 ± 0.32 5.72 2.1
Absolute error 2.4 ± 0.7
a Mean ± SD, n = 3.
Fig. 4. Differential scanning calorimetric thermograms of: glipizide (A), placebo lipospheres (B) and
optimized liposphere formulation (C).
Differential scanning analysis was performed to characterize the solid state of the
drug in the wax matrix. The DSC thermogram of glipizide exhibited a sharp endother-
mic peak at 212 °C corresponding to its melting transition point (Fig. 4). The thermo-
gram of the placebo liposphere formulation displays a sharp peak at 58 °C correspond-
ing to the melting point of the stearic acid-paraffin wax mixture. This clearly indicated
the lowering of the melting point of paraffin wax (melting point 62 °C) in the presence of
stearic acid. The appearance of the sharp low intensity endothermic peak in the ther-
mogram of the optimized liposphere formulation (F10) at 206 °C suggested that the drug
may be present in the molecular as well as microcrystalline state in the wax matrix, which
could also explain the sustained drug release from the liposphere formulations.
In vivo efficiency tests of the pure glipizide and optimized liposphere formulation (F10)
were performed on albino Wistar rats by measuring the hypoglycemic effect produced after
oral administration. Pure glipizide and the optimized liposphere formulation were adminis-
tered at a dose equivalent to 800 mg kg–1. With pure glipizide, a rapid reduction in blood
glucose levels was observed with maximum reduction of 52.72 ± 5.26% within 2 hours after
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Fig. 5. Percentage reduction in
serum glucose levels following
oral administration of glipizide
and the optimized liposphere
formulation (mean ± SD, n = 4).
oral administration. Following the drug administration, the blood glucose levels recovered
to normal within 8 hours in case of the pure drug (Fig. 5). The reduction in blood glucose
levels was gradual and reached maximum reduction (46.22 ± 4.31%) 6 hours after the ad-
ministration of optimized glipizide lipospheres. This reduction in blood glucose levels was
sustained for longer periods of time (16 hours). A 25% reduction in blood glucose levels is
considered a significant hypoglycemic effect (22). Significant hypoglycemic effect was ob-
served between 1 and 6 hours after oral administration of glipizide, whereas with lipo-
spheres, a significant hypoglycemic effect was maintained for 3 to 16 hours after adminis-
tration. One can speculate that the glipizide particles are voided from the stomach much
quicker than the lipospheres, and then they immediately dissolve in the duodenal fluid
with higher pH and get absorbed. This may not be the case with the drug loaded liposphe-
res, where the sustained hypoglycemic effect may be due to longer gastric transit time and
slower release of glipizide in the duodenum.
CONCLUSIONS
The modified hydrophobic congealable dispersed phase encapsulation procedure used
to produce glipizide lipospheres is simple, rapid, inexpensive and reproducible. The lipo-
spheres developed employing a 32 factorial design showed high drug encapsulation effi-
ciency and exhibited a sustained release property for peroral use in the form of capsules.
Wax loads as well as the stearic acid levels had a significant influence on the encapsula-
tion efficiency and the drug release. The optimized formulation developed using the de-
sirability approach produced sustained anti-diabetic activity in rats following oral ad-
ministration.
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S A @ E T A K
Dizaj i statisti~ka optimizacija liposfera s glipizidom pomo}u
metodologije odgovora povr{ine
HAGALAVADI NANJAPPA SHIVAKUMAR, PRAGNESH BHARAT BHAI PATEL, BAPUSAHEB GANGADHAR DESAI,
PURNIMA ASHOK i SINNATHAMBI ARULMOZHI
32 faktorijalni dizajn je primijenjen za pripravu liposfera s glipizidom metodom se-
paracije pomo}u emulzija koriste}i parafinski vosak i stearinsku kiselinu kao tvari za us-
poravanje. Pomo}u F-testa pra}en je u~inak kriti~nih varijabli tijekom formuliranja, tj.
koli~ina parafinskog voska (X1) i udio stearinske kiseline (X2) na srednji promjer lipo-
sfera (dg), postotak inkapsulirane ljekovite tvari (% EE), osloba|anje ljekovite tvari na-
kon 12 h (rel12) te vrijeme potrebno za osloba|anje 50% ljekovite tvari (t50). Za svaki para-
metar su pomo}u multiple linearne regresijske analize (MLRA) i analize varijabli (ANOVA)
na~injeni matemati~ki modeli koji sadr`e samo zna~ajne varijable. Prou~avanje varijabli
na oba na~ina ukazalo je na njihov zna~ajan utjecaj (p < 0,05) na parametre liposfera.
Postavljanjem ograni~enja na zavisne i nezavisne varijable provedena je numeri~ka opti-
mizacija na principu po`eljnosti. Eksperimentalne vrijednosti dg, % EE, rel12 i t50 optimi-
ziranih formulacija bile su 57,54 ± 1,38 mm, 86,28 ± 1,32%, 77,23 ± 2,78% i 5,60 ± 0,32 h.
Dobivene eksperimentalne vrijednosti bile su vrlo sli~ne vrijednostima predvi|enim mate-
mati~kim modelima. Osloba|anje glipizida iz liposfera slijedio je kinetiku prvog reda i
karakteriziran je Higuchijevim difuzijskim modelom. Optimizirane liposfere su nakon
peroralne primjene na {takorima pokazale produljeni antidijabeti~ki u~inak.
Klju~ne rije~i: liposfere, glipizid, faktorijalni dizajn, metodologija odgovora povr{ine, optimizacija
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